News

The project is aimed at exploring a genetic cause in hereditary forms of the disease as a platform for developing disease-modifying treatment that would slow or stop the

With this approval, physicians who treat adults with chronic or accelerated phase CML who are no longer responding to, or who could not tolerate, two or more tyrosine

Abilify Maintena is the first product in Canada from the global alliance between Otsuka and Lundbeck, which is focused on developing central nervous system (CNS) therapies worldwide. Abilify

NanoAntibiotics president and director Rajah Menon noted that the company is excited to be making its debut in the public marketplace and committed to providing its investors with

ChromaDex will provide Wageningen University with quantities of its proprietary NIAGEN nicotinamide riboside (NR) ingredient for research use. ChromaDex’s NIAGEN is the first and only commercially available form

Under this collaborative initiative, FORMA and Dr Ovaa will advance the research, discovery and clinical application of highly-selective, irreversible therapeutics. This represents a distinct and additional agreement between

This is the Company’s second IND to be allowed in the past 10 months that uses the Orascovery technology platform for oral delivery of anti-cancer drugs. In July

Under the collaboration, new gene therapy vectors and proprietary molecules will be discovered and developed using the Avalanche Ocular BioFactory, an adeno-associated virus (AAV)-based, proprietary, next-generation platform for

Auven intends to conduct a Phase II (proof-of-concept) clinical trial to evaluate KIACTA’s effectiveness and safety to treat certain medical manifestations of sarcoidosis. Kiacta is aimed at addressing